JRC Publications Repository

JRC Publications Repository >

Browsing by Author MORGENSTERN Alfred

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:   
Sort by: In order: Results/Page Authors/Record:
Showing results 70 to 89 of 127
Publication YearTitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2010Investigation of Para-sulfonatocalix[n]arenes [n = 6, 8] as Potential Chelates for 230UMONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2010Investigation of para-sulfonatocalix[n]arenes [n = 6, 8] as potential chelates for 230U†MONTAVON Gilles; REPINC Urska; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; ABBAS Kamel; MORGENSTERN AlfredArticles in Journals
2012Is DTPA a good competing chelating agent for Th(IV) in human serum and suitable in targeted alpha therapy?LE DU Alicia; SABATIE-GEGOVA Andrea; MORGENSTERN Alfred; MONTAVON GillesArticles in Journals
2011Magnetic Memory Effect in a Transuranic Mononuclear ComplexMAGNANI Nicola; APOSTOLIDIS Christos; MORGENSTERN Alfred; COLINEAU Eric; GRIVEAU Jean-Christophe; BOLVIN Hélène; WALTER OLAF; CACIUFFO RobertoArticles in Journals
2011Magnetic Memory Effect in a Transuranic Mononuclear ComplexMAGNANI Nicola; APOSTOLIDIS Christos; MORGENSTERN Alfred; COLINEAU Eric; GRIVEAU Jean-Christophe; WALTER Olaf; CACIUFFO RobertoArticles in Journals
2013Measurement and modelling of the cross sections for the reaction 230Th(3He,3n)230UMORGENSTERN Alfred; ABBAS Kamel; SIMONELLI Federica; CAPOTE NOY R.; SIN M.; ZIELINSKA B.; BRUCHERTSEIFER Frank; APOSTOLIDIS ChristosArticles in Journals
2012Measurement of the 225Ac half-lifePOMME Stefaan; MAROULI MARIA; SULIMAN GABRIEL; DIKMEN HASAN; VAN AMMEL Raf; JOBBAGY VIKTOR; DIRICAN A.; STROH HEIKO; PAEPEN Jan; BRUCHERTSEIFER Frank, et alArticles in Journals
2012Measurement of the 226Th and 222Ra half-livesPOMME Stefaan; SULIMAN GABRIEL; MAROULI MARIA; VAN AMMEL Raf; JOBBAGY VIKTOR; PAEPEN Jan; STROH HEIKO; APOSTOLIDIS Christos; ABBAS Kamel; MORGENSTERN AlfredContributions to Conferences
2012Measurement of the 230U half-lifePOMME Stefaan; ALTZITZOGLOU Timotheos; VAN AMMEL Raf; SULIMAN GABRIEL; MAROULI MARIA; JOBBAGY VIKTOR; PAEPEN Jan; STROH HEIKO; APOSTOLIDIS Christos; ABBAS Kamel, et alContributions to Conferences
2012Measurements of the half-life of 214Po and 218Rn using digital electronicsSULIMAN GABRIEL; POMME Stefaan; MAROULI MARIA; VAN AMMEL Raf; JOBBAGY VIKTOR; PAEPEN Jan; STROH HEIKO; APOSTOLIDIS Christos; ABBAS Kamel; MORGENSTERN AlfredContributions to Conferences
2014Microbicidal Power of Alpha Radiation in Sterilizing Germinating Bacillus anthracis SporesRIVERA J.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; KEARNEY John; TURNBOUGH Charles; DADACHOVA E.; Casadevall ArturoArticles in Journals
2007Non-invasive Visualisation of the Development of Peritoneal Carcinomatosis and Tumour Regression After 213Bi-radioimmunotherapy Using Bioluminescence ImagingBUCHHORN H.m.; SEIDL C.; BECK R.; SAUR D.; APOSTOLIDIS CHRISTOS; MORGENSTERN ALFRED; SCHWAIGER M.; SENEKOWITSCH-SCHMIDTKE R.Articles in Journals
2012Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostateRIZVI S.m.a.; ALLEN B.j.; LEE C.s.; BRUCHERTSEIFER Frank; MORGENSTERN Alfred; APOSTOLIDIS Christos; CLARKE R.a.Articles in Journals
2007Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in Preclinical Targeted Alpha Therapy for CancerSONG E.; ABBAS RIZVI S. M.; QU C. F.; RAJA C.; BRECHBIEL M. W.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2012Polymersomes as nano-carriers to retain harmful recoil nuclides in alpha radionuclide therapy: a feasibility studyTHIJSEN L.; SCHAART D.r.; DE VRIES D.; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; DENKOVA A.g.Articles in Journals
2005Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic CancerQU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J.; MORGENSTERN ALFREDArticles in Journals
2006Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft ModelRIZVI S.m.a.; LI Y.; SONG E.; QU C.f.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B.j.Articles in Journals
2008Preparation and Testing of Bevacizumab Radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206RIZVI S.; SONG E.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; RUSSELL P. J.; KEARSLEY J.; ABBAS Kamel; ALLEN B. J.Articles in Journals
2008Production of 230U/226Th for Targeted Alpha Therapy via Proton Irradiation of 231PaMORGENSTERN Alfred; LEBEDA O.; STURSA J.; BRUCHERTSEIFER Frank; CAPOTE R.; MCGINLEY John; RASMUSSEN Gert; SIN M.; ZIELINSKA B.; APOSTOLIDIS ChristosArticles in Journals
2005Production of Ac-225 from Th-229 for Targeted Alpha TherapyAPOSTOLIDIS CHRISTOS; MOLINET Roger; MORGENSTERN ALFREDArticles in Journals
Showing results 70 to 89 of 127

 

The mission of the JRC is to provide customer-driven scientific and technical support for the conception, development, implementation and monitoring of EU policies. As a service of the European Commission, the JRC functions as a reference centre of science and technology for the Union. Close to the policy-making process, it serves the common interest of the Member States, while being independent of special interests, whether private or national.
Powered by DSpace
Top